Who Paid My Doc
A Phase 3, Observer-Blind, Randomized, Placebo Controlled Study to Eva
Research payments
$2,048,850
Through program year 2024, $2,048,850 in research payments was reported against A Phase 3, Observer-Blind, Randomized, Placebo Controlled Study to Eva, across 213 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $103,188 | 18 |
| 2023 | Research | $1,924,862 | 187 |
| 2022 | Research | $20,800 | 8 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Terry Poling Wichita, KS Named on 19 payments
- Kevin Cannon Winston Salem, NC Named on 15 payments
- Anton Grasch Wenatchee, WA Named on 13 payments
- Pedro Ylisastigui Fort Myers, FL Named on 12 payments
- Matthew Davis Rochester, NY Named on 10 payments
- Robert Noveck New Orleans, LA Named on 10 payments
- Michael Ledet Mobile, AL Named on 10 payments
- William Smith New Orleans, LA Named on 9 payments
- Joseph Soufer Waterbury, CT Named on 9 payments
- Laura Helman South Bend, IN Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.